The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
August 20th, 2014
11.7K views
Blood exposure to polymeric blood conduits initiates the foreign body reaction that has been implicated in clinical complications. Here, the Chandler Loop Apparatus, an experimental tool mimicking blood perfusion through these conduits, is described. Appendage of recombinant CD47 results in decreased evidence of the foreign body reaction on these conduits.
Overview
This study investigates the biocompatibility of polymers modified with recombinant CD47 using the Chandler Loop model to simulate blood perfusion. The results indicate that recombinant CD47 enhances polymer compatibility and reduces the foreign body reaction.
Key Study Components
Area of Science
- Biomaterials
- Blood compatibility
- Foreign body reaction
Background
- Polymeric blood conduits can trigger foreign body reactions.
- These reactions are linked to clinical complications in medical devices.
- Recombinant CD47 is hypothesized to improve biocompatibility.
- The Chandler Loop Apparatus mimics blood flow through conduits.
Purpose of Study
- To assess the biocompatibility of CD47-modified polymers.
- To evaluate the foreign body reaction in a controlled environment.
- To provide insights for improving implanted medical devices.
Methods Used
- Modification of polymers with recombinant CD47.
- Use of photo activation chemistry for polymer modification.
- Exposure of modified polymers to human blood in the Chandler Loop.
- Cell fixation and staining to quantify adhered cells.
Main Results
- Recombinant CD47 significantly reduces cell adhesion on polymers.
- Modified polymers show improved biocompatibility compared to unmodified ones.
- Less foreign body rejection is observed with CD47 modification.
- The study provides a method to enhance the performance of implanted devices.
Conclusions
- Recombinant CD47 enhances the biocompatibility of polymers.
- This modification can mitigate foreign body reactions.
- The findings have implications for the design of medical implants.
Frequently Asked Questions
What is the Chandler Loop Apparatus?
It is an experimental tool that mimics blood perfusion through polymeric conduits.
How does recombinant CD47 affect biocompatibility?
It reduces cell adhesion, thereby improving the biocompatibility of polymers.
What are the implications of this study?
The findings can help in designing better medical implants with reduced rejection rates.
What methods were used to assess biocompatibility?
Cell fixation and staining were used to quantify adhered cells on the polymers.
Why is reducing the foreign body reaction important?
It is crucial for the success and longevity of implanted medical devices.
What role does photo activation chemistry play in this study?
It is used to modify the polymers with recombinant CD47 before blood exposure.
Executive Industry Relevance
Assessing the biocompatibility of polymeric blood conduits is critical for reducing implant failure and foreign body reactions in cardiovascular device development. The Chandler Loop Apparatus provides an ex vivo model to evaluate surface modifications under physiological blood flow conditions, enabling early de-risking of biomaterials. This approach supports target validation by linking CD47-mediated anti-inflammatory effects to improved device hemocompatibility and translational potential.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of CD47's role in suppressing monocyte/macrophage adhesion and inflammatory signaling on polymeric surfaces.
- Operational Value: Provides a quantitative readout of cell adhesion to assess target engagement and functional biocompatibility.
- Predictive Value: Supports mechanistic de-risking by demonstrating reduced foreign body response in a blood perfusion model.
Screening & Assay Development
- Assay Readiness: Generates standardized, reproducible data on cell attachment to modified vs. control polymeric conduits.
- Quantitative Output: Uses DPI staining and fluorescence quantification to measure recombinant CD47 binding and anti-adhesive effects.
- Platform Utility: Establishes a perfusion-based assay format suitable for screening other immunomodulatory surface modifications.
Translational & Preclinical Research
- Disease Relevance: Models human blood interaction with implanted conduits, relevant to vascular graft and extracorporeal circuit applications.
- Translational Continuity: Bridges in vitro surface modification with ex vivo hemodynamic testing to inform preclinical device design.
- Risk-Adjusted Advancement: Supports go/no-go decisions by correlating CD47 density with reduced cell adhesion and improved biocompatibility.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through assay development to preclinical evaluation, particularly for immunomodulatory biomaterials.
- Discovery Biology: Tests the hypothesis that CD47 engagement with SIRPα reduces phagocytic and inflammatory cell activation on foreign surfaces.
- Screening: Enables side-by-side comparison of surface modifications under controlled shear stress and blood exposure.
- Analytics: Delivers quantitative fluorescence and microscopy-based readouts for binding efficiency and functional inhibition of cell adhesion.
- Translational Research: Connects molecular surface engineering to hemocompatibility outcomes in a clinically relevant perfusion model.
- Enterprise Reuse: The Chandler Loop platform can be adapted to evaluate other recombinant proteins or peptide coatings for blood-contacting devices.
Operational & Enterprise Impact
- Scientific Value: Mechanistic insight into CD47-mediated suppression of inflammatory cell attachment and foreign body initiation.
- Operational Value: Standardized perfusion conditions, reproducible cell quantification, and adaptable surface chemistry workflow.
- Strategic Value: Informs early-stage biomaterial selection, reducing late-stage failure due to thrombotic or inflammatory complications.
- Portfolio Impact: Enables risk-adjusted prioritization of polymer-CD47 conjugates based on hemocompatibility performance.
Implementation Considerations
- Requires expertise in protein conjugation, photoactivation chemistry, and sterile blood handling under IRB-approved protocols.
- Depends on Chandler Loop apparatus, UV irradiation system, and fluorescence microscopy or plate reader for quantification.
- Necessitates standardization across teams for tube preparation, blood perfusion timing, and post-exposure washing to ensure reproducibility.
- Adaptation to other polymeric materials (e.g., PVC, silicone) may require optimization of surface activation and protein coupling efficiency.
- Practical limitations include donor variability in blood response and the semi-static nature of the ex vivo model compared to in vivo hemodynamics.
Biopharma FAQs
Why does measuring adhered cell count matter for target validation of CD47?
Measuring adhered cell count via DPI staining quantifies the extent of monocyte/macrophage attachment, which reflects inflammatory activation and foreign body response. A significant reduction in cell adhesion on CD47-modified surfaces indicates successful target engagement and functional immunomodulation. This metric serves as a direct functional readout for validating CD47’s mechanism of action in preventing immune recognition of polymeric surfaces.
How does isolating the independent variable (CD47 modification) support discovery pipeline decisions?
By comparing recombinant CD47-modified conduits to unmodified controls under identical perfusion conditions, the study isolates CD47 as the independent variable influencing biocompatibility. This enables clear attribution of reduced cell adhesion to the surface modification rather than confounding factors. Such controlled comparison is essential for de-risking target hypotheses and guiding investment in lead optimization.
What do quantitative dependent variable measurements enable in biomaterials screening?
Quantitative measurements of recombinant CD47 binding (via fluorescence) and cell adhesion (via DPI staining) provide objective, comparable data across test conditions. These outputs allow ranking of surface modifications by hemocompatibility performance and establish structure-function relationships. Such data are critical for setting go/no-go thresholds in preclinical biomaterial evaluation.
Why do replication requirements matter for cross-functional collaboration in device development?
Replication across multiple tubing samples and experimental runs ensures that observed reductions in cell adhesion are consistent and not due to procedural variability. Reliable, reproducible results build confidence among R&D, toxicology, and translational teams when assessing biomaterial safety. Standardized replication supports technology transfer and regulatory readiness for implanted device evaluation.
What statistical analysis capabilities are required before implementing the Chandler Loop assay?
The assay requires statistical comparison of cell adhesion between modified and control groups, typically using t-tests or ANOVA to determine significance. Proper experimental design includes replicates, controls, and blinded quantification to avoid bias. These capabilities are essential to validate that observed biocompatibility improvements are statistically robust and not due to random variation.
